OptiTROP-Breast05: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer (clinicaltrials.gov) - Aug 29, 2026 - P2 | N=184 | Completed | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Sep 2027 ➔ Jul 2026 | Trial primary completion date: Sep 2027 ➔ Jul 2026
Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2
|